A recent issue of Bone Marrow Transplantation included the results of a clinical trial from Minnesota of 15 pediatric patients who were transplanted with umbilical cord blood in combination with pre-expanded MSCs in an attempt to accelerate hematopoietic recovery. 1 According to our present understanding, MSCs, osteoblasts and other stromal cells, including sinusoidal and endothelial, are responsible for supporting hematopoiesis and controlling HSC number. Therefore a co-transplantation of these cells, together with HSC, can be more effective in the reconstitution of hematopoiesis. This approach is especially attractive for cases with a predicted poor engraftment due to both an insufficient number of transplanted HSCs or impaired stroma.
As far back as the early 1970s, Friedenstein 2 showed that MSCs support hematopoiesis after local transplantation and lose this ability after i.v. BMT. Nevertheless, starting from 2000, several groups, including the group from Minnesota, have reported data showing their experience with the use of MSCs in adults or children with malignant or nonmalignant diseases, after myeloablative or reducedintensity conditioning, in transplant from autologous, matched sibling or mismatched T-cell-depleted graft, including BM, PBSCs or umbilical cord blood as a source of hematopoietic stem cells. 1, [3] [4] [5] [6] [7] [8] In spite of the variability of the cases, several conclusions can be drawn from these trials. First, except for one case of urticaria, 9 any immediate side effects from an i.v. transfusion of MSCs were not described. Second, the kinetics and homing of MSCs were evaluated in some studies: Koc et al. 3 detected infused MSCs in circulation up to 1 h after infusion of autologous MSCs; Lazarus et al. 4 found donor-derived MSCs in shortterm MSC cultures from 2 out of 18 patients; Ball et al. 5 found minimal (1-2%) and transient chimerism in ex vivo expanded MSCs in 3 out of 14 patients; and only Poloni et al., 6 using PCR and FISH found a reasonable mixed chimerism of stromal cells in 8 out of 22 patients, which was reversible in 4 of them (7-86% up to 30 months after transplantation). Last but not the least, none of the above mentioned studies showed a clinically significant association between infusion of MSC, number of MSCs, stromal chimerism and hematopoietic engraftment.
On the basis of our experience with MSCs, we discuss here two key elements distinguishing these cells from HSCs in terms of transplantation practice: they are much bigger than PBMCs and they express very strong adhesion properties. Moreover, single-cell suspensions of MSCs are extremely unstable and they start to agglutinate within several minutes, making conglomerates of dozens of cells. Therefore, a distribution of these cells after i.v. infusion clashes with the major difficulty of overcoming the lung barrier. This problem can be partially overcome by sodium nitroprusside infusion, as shown in animal models 10 (Resnick et al., unpublished data).
In this study, we briefly present a 3-year-old boy with a diagnosis of Wiskott-Aldrich syndrome with severe manifestations (recurrent opportunistic infections, eczema, deep thrombocytopenia with bleeding tendency, lymphocytopenia o200 per mcl, autoimmunity) who had no matched sibling or unrelated donor, but a good enough matched umbilical cord blood with sufficient cell number. The above considerations and poor prognosis with a short life expectancy helped us us to decide to carry out a standard haploidentical HSCT from his mother, combined with a direct intraosseous injection of pre-expanded MSCs from the same donor.
At 3 weeks before transplantation, 120 ml of BM was collected from the iliac crest of the patient's mother and MSCs were expanded as previously described.
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After conditioning with fludarabine 180 mg/m 2 , busulfex 8 mg/kg, endoxan 120 mg/kg, thiotepa 10 mg/kg and ATG (Thymoglobulin) 10 mg/kg, the patient received an intraosseous injection of 3 Â 10 6 per kg MSCs, suspended in 10 ml of NS into the left side of the iliac crest in six closely grouped locations. The procedure was uneventful. After 2 h, 33.7 Â 10 6 per kg of positively selected CD34 þ cells was infused i.v. Engraftment of ANC 4500 per mcl was observed on day þ 25, but the patient remained pancytopenic. WBC chimerism at that time was 95%. Owing to poor clinical engraftment, BM aspiration and biopsy were performed from both sides of the iliac crest. Morphological findings were clearly different: on the right side of the pelvic bone, BM was aplastic, on the left side, cellularity was close to 50% with three-lineage hematopoiesis (Figure 1) . DNA from the layer of shortly expanded MSCs was analyzed using STR analysis, which showed just a questionable trace of stromal cell chimerism on the MSC injection side. With time, the patient started to restore host-type hematopoiesis, but developed severe generalized candidiasis. He was boosted with donor CD34 þ cells (6.7 Â 10 6 per kg) on day þ 118, with no improvement in his counts and chimerism (app. 20%). Finally, because of granulocytopenia, the patient received a backup of his own marrow (day þ 133). Despite this fact, he has maintained donor-type chimerism of the whole WBC population from 15 to 75% and has no deep lymphocytopenia (500-800 per mcl).
Despite the poor results of the transplantation itself, our case directly shows that intraosseous injection of donor origin MSCs with similar exposure to purified HSC (i.v. infusion) and condition of host-type stroma may facilitate donor-type hematopoiesis in situ, even with a low degree of stromal chimerism. The area of hematopoietic stroma supporting hematopoiesis remained small and was not sufficient for substantial general hematopoiesis recovery. New paths of targeted cell delivery omitting the lung barrier, such as multiple intra-osseous, intra-arterial and so on, should be carefully investigated as a potentially major way to improve results of MSC transplantation. Figure 1 Biopsies from iliac bone after WBC engraftment at day þ 60 after transplantation. The site of MSC transplantation has a much better cellularity with three-lineage hematopoiesis (magnification power Â 10, arrows show megakaryocytes in magnification Â 60).
